Comprehensive insights on ARPIs (androgen receptor pathway inhibitors) for the treatment of prostate cancer, highlighting what influences treatment decisions and safety profiles of the available APRIs.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.